143 related articles for article (PubMed ID: 35900907)
1. Bone marrow overexpression of SNAI1 is an early indicator of intrinsic drug resistance in patients with de novo acute myeloid leukemia.
Gouda MBY; Hassan NM; Kandil EI
J Gene Med; 2023 May; 25(5):e3443. PubMed ID: 35900907
[TBL] [Abstract][Full Text] [Related]
2. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
[TBL] [Abstract][Full Text] [Related]
3. HLA-DR antigen-negative acute myeloid leukemia.
Wetzler M; McElwain BK; Stewart CC; Blumenson L; Mortazavi A; Ford LA; Slack JL; Barcos M; Ferrone S; Baer MR
Leukemia; 2003 Apr; 17(4):707-15. PubMed ID: 12682628
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical significance of SNAI1 and ZEB1 genes in acute myeloid leukemia patients.
Shousha WG; Ramadan SS; El-Saiid AS; Abdelmoneim AE; Abbas MA
Mol Biol Rep; 2019 Aug; 46(4):4625-4630. PubMed ID: 31055699
[TBL] [Abstract][Full Text] [Related]
5. CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations.
Gajendra S; Gupta R; Thakral D; Gupta SK; Jain G; Bakhshi S; Sharma A; Sahoo RK; Kumar L; Rai S; Singh S; Upadhyay AD
Int J Lab Hematol; 2023 Apr; 45(2):221-228. PubMed ID: 36504282
[TBL] [Abstract][Full Text] [Related]
6. [Clinical analysis of HLA-DR-negative non-M3 AML].
Mori H; Sakai H; Sanada M; Shimamoto K; Sasaki S; Azuma R; Higuchi T; Harada H; Niikura H; Omine M; Fujita K; Takahashi N
Rinsho Ketsueki; 2007 Jul; 48(7):547-53. PubMed ID: 17695303
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological features in HLA-DR-negative acute myeloid leukemia].
Muroi K; Yoshida M; Suzuki T; Amemiya Y; Hatake K; Miura Y
Rinsho Ketsueki; 1997 Aug; 38(8):631-7. PubMed ID: 9311267
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.
Kaleem Z; Crawford E; Pathan MH; Jasper L; Covinsky MA; Johnson LR; White G
Arch Pathol Lab Med; 2003 Jan; 127(1):42-8. PubMed ID: 12521365
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
[TBL] [Abstract][Full Text] [Related]
12. Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.
Fabiani E; Cicconi L; Nardozza AM; Cristiano A; Rossi M; Ottone T; Falconi G; Divona M; Testi AM; Annibali O; Castelli R; Lazarevic V; Rego E; Montesinos P; Esteve J; Venditti A; Della Porta M; Arcese W; Lo-Coco F; Voso MT
Cancer Med; 2021 Jun; 10(12):3839-3847. PubMed ID: 34042280
[TBL] [Abstract][Full Text] [Related]
13. PROFILE OF CD150 EXPRESSION IN BONE MARROW CELLS OF PATIENTS WITH ACUTE MYELOID LEUKEMIA.
Shlapatska L; Gordiienko I; Polishchuk A; Gluzman D
Exp Oncol; 2022 Nov; 44(3):198-207. PubMed ID: 36325710
[TBL] [Abstract][Full Text] [Related]
14. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
Munker R; Andreeff M
Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
[TBL] [Abstract][Full Text] [Related]
15. Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience.
Pagnano KB; Traina F; Takahashi T; Oliveira GB; Rossini MS; Lorand-Metze I; Vigorito AC; Miranda EC; De Souza CA
Sao Paulo Med J; 2000 Nov; 118(6):173-8. PubMed ID: 11120548
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases.
Zhang PJ; Barcos M; Stewart CC; Block AW; Sait S; Brooks JJ
Mod Pathol; 2000 Apr; 13(4):452-8. PubMed ID: 10786814
[TBL] [Abstract][Full Text] [Related]
17. [FLT3-ITD and NPM1 mutation positive acute myeloid leukemia with cuplike blasts mimicking acute promyelocytic leukemia].
Aoyama K; Yamasaki Y; Mouri F; Maehiro Y; Takaki Y; Oya S; Nakamura T; Morishige S; Yamaguchi M; Nagafuji K
Rinsho Ketsueki; 2022; 63(7):764-769. PubMed ID: 35922945
[TBL] [Abstract][Full Text] [Related]
18. Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome.
Roerden M; Märklin M; Salih HR; Bethge WA; Klein R; Rammensee HG; Nelde A; Walz JS
Leuk Lymphoma; 2021 Aug; 62(8):1907-1919. PubMed ID: 33648413
[TBL] [Abstract][Full Text] [Related]
19. Adult acute leukemia.
Cripe LD
Curr Probl Cancer; 1997; 21(1):1-64. PubMed ID: 9058027
[TBL] [Abstract][Full Text] [Related]
20. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
